Posts Archive

NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) + Dex

NCT05136807: Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

The PCROWD Study invites people with precursor conditions to Share samples a few times each year

NCT05014646: Phase 2: Leflunomide for High-Risk Smoldering MM in African-Am. & European-Am. Patients

NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)

NCT04776395: Phase 2: Iberdomide Alone or in Combination With Dex for Intermediate/High-Risk SMM

NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor MM

NCT04920084: A Study of a Plant-Based Diet in People With MGUS / Smoldering Myeloma - NUTRIVENTION

NCT04512235: Phase 3: To Evaluate Effectiveness & Safety of CAEL-101 in Stage IIIa AL Amyloidosis

IMPACT Study: The Immune Profiling with Antibody-based COVID-19 Testing - COVID-19 antibodies test

The clonoSEQ® Watch Registry

NCT04504825: Phase 3: Efficacy & Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis

NCT04270409: Phase 3 - Isatuximab in Combination With Lenalidomide and Dex High-risk SMM (ITHACA)

NCT04144387: IFM2017 Evaluation of the Impact of the Update SMM Criteria on the Natural History SMM

NCT03850522: Phase 2: PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma

NCT03937635: Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma DETER-SMM

NCT03839459: Phase 2: Denosumab for Smoldering Multiple Myeloma

NCT03820817: Phase 1: Rifaximin in Patients With Monoclonal Gammopathy

NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population